544220 CTLLAB

Clinitech Laboratory Share Price

₹78.87 +11.87 (17.72%)

28 Dec, 2024 01:53

SIP TrendupStart SIP in CTLLAB

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -0.16%
  • Over 3 Month + 1.9%
SIP Lightning

Smart Investing Starts Here Start SIP with Clinitech Laboratory for Steady Growth!

Invest Now

Clinitech Laboratory Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Clinitech Laboratory Financials

Clinitech Laboratory Technicals

EMA & SMA

Current Price
₹78.87
+ 11.87 (17.72%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 2
  • 20 Day
  • ₹76.00
  • 50 Day
  • ₹81.11
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

75.91 Pivot Speed
  • R3 90.70
  • R2 84.78
  • R1 81.83
  • S1 72.96
  • S2 67.04
  • S3 64.09

What's your outlook on Clinitech Laboratory?

You can only vote for once

Clinitech Laboratory Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Half Yearly Results

Clinitech Laboratory F&O

Clinitech Laboratory Shareholding Pattern

No data available.

About Clinitech Laboratory

  • NSE Symbol
  • CTLLAB
  • BSE Symbol
  • 544220
  • ISIN
  • INE0QMR01015

Similar Stocks to Clinitech Laboratory

Clinitech Laboratory FAQs

Clinitech Laboratory share price is ₹78 As on 28 December, 2024 | 01:39

The Market Cap of Clinitech Laboratory is ₹18 Cr As on 28 December, 2024 | 01:39

The P/E ratio of Clinitech Laboratory is As on 28 December, 2024 | 01:39

The PB ratio of Clinitech Laboratory is 7.6 As on 28 December, 2024 | 01:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23